poisar

Stocks · News reference

Needham Maintains Buy Rating on Collegium Pharmaceutical, Lowers Price Target

Fiscal.ai

Needham & Company maintained its 'Buy' rating on Collegium Pharmaceutical while adjusting its price target from $46 to $44.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. BenzingaEarnings Transcripts

    Collegium Pharmaceutical Q3 2026 Earnings Call Transcript

    Collegium Pharmaceutical (NASDAQ:COLL) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by

  2. SEC EDGARSEC EDGAR

    8-K filing — COLLEGIUM PHARMACEUTICAL, INC (COLL)

    Filed: 2026-11-05 AccNo: 0001628280-26-070585 Size: 3 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

  3. Globenewswire IncNa

    Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts

    Collegium Pharmaceutical and Boston Legacy FC announced an expanded multi-year partnership to support neurodivergent children and families across Massachusetts. The partnership includes a soccer coaching certification initiative to train coaches in supporting children with ADHD, an annual Sports for All Summit, and continued sensory inclusion programs. Collegium will also increase its presence as an Official Partner with branding on Boston Legacy FC's game kits and stadium signage ahead of its headquarters move to Boston in early 2027.